NextCell publishes its Interim Report 1 2022/2023

January 26, 2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First quarter (2022-09-01 until 2022-11-30)

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stem cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to a market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical Covid-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100%of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2026-10-26

NextCell reports encouraging numerical results in younger children – strategy for adults remains unchanged

NextCell Pharma AB (publ) (“NextCell” or the “Company”) today announces the 12-month results from ProTrans-Young. In the predefined age group of 7–11 years, children treated with NXTCL-T1D had, on average, preserved a greater proportion of their endogenous insulin production after 12 months and experienced a smaller increase in insulin requirements compared with those receiving placebo. The study did not meet its primary efficacy endpoint in the overall study population. A preliminary analysis of 24-month data from the older age group shows no clear treatment effect, although the data have not yet been fully analysed or validated. NextCell’s commercialisation strategy for adults remains unchanged, while the Company intends to refine its treatment strategy for children and adolescents, focusing on treatment timing and the number of administrations. Further analyses are also planned to investigate how age and individual disease progression may influence treatment response.

Read more Read more

2026-10-19

NextCell provides update on timing of ProTrans-Young results

NextCell Pharma AB (publ) (“NextCell” or the “Company”) announces that topline results from the ProTrans-Young clinical trial have not yet been reported to the company. The extended timeline is due to the final administrative processing and sign-off of study data taking longer than planned and is not related to the outcome of the study. The data are now being handled by statisticians at Uppsala Clinical Research Center (UCR).

Read more Read more

2026-09-28

NextCell to present at the INNODIA Symposium during EASD 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell’s clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

Read more Read more

2026-08-27

Interim Report second quarter 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

Read more Read more

2026-08-18

NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

Read more Read more

2026-05-28

Interim Report first quarter 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

Read more Read more

2026-05-27

NextCell Pharma AB (publ) Annual General Meeting 2026

On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.

Read more Read more

2026-05-06

NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.

Read more Read more

NextCell publishes its Interim Report 1 2022/2023

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.